A 6-Month Follow-up of Intermittent Levosimendan Administration Effect on Systolic Function, Specific Activity Questionnaire, and Arrhythmia in Advanced Heart Failure

Journal of Cardiac Failure

Volumn 13, Issue 7, 2007, Pages 556-559

  Mavrogeni, Sophie ^a   Giamouzis, Gregory ^a   Papadopoulou, Evangelia ^a   Thomopoulou, Sophia ^a   Dritsas, Athanasios ^a   Athanasopoulos, George ^a   Adreanides, Elias ^a   Vassiliadis, Ioannis ^a   Spargias, Konstantinos ^a   Panagiotakos, Dimosthenis ^a   Cokkinos, Dennis V ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

Heart failure; levosimendan

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LEVOSIMENDAN; NITRATE;

ADULT; AGED; APPARATUS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFECT; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DYSPNEA; ECHOCARDIOGRAPHY; FATIGUE; FEMALE; FOLLOW UP; GREECE; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE EJECTION FRACTION; HOLTER MONITORING; HUMAN; MALE; MITRAL VALVE REGURGITATION; OUTCOME ASSESSMENT; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SPECIFIC ACTIVITY QUESTIONNAIRE; SYSTOLE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDRAZONES; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; MYOCARDIAL CONTRACTION; PYRIDAZINES; QUESTIONNAIRES; STROKE VOLUME; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 34548448464     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2007.04.004     Document Type: Article

References (17)

1. Parissis J., Filippatos G., Farmakis D., Adamopoulos S., Paraskevaidis I., and Kremastinos D. Levosimendan for the treatment of acute heart failure syndromes. Expert Opin Pharmacother 6 (2005) 2741-2751
2. Todaka K., Wang J., Yi G.H., et al. Effects of levosimendan on myocardial contractility and oxygen consumption. J Pharmacol Exp Ther 279 (1996) 120-127
3. Kiviko M., Antila S., Eha J., Lehtonen L., and Pentikainen P. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol 42 (2002) 43-51
4. Hasenfuss G., Pieske B., Castell M., Kretschmann B., Maier L.S., and Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 98 (1998) 2141-2147
5. Yokoshiki H., Katsube Y., Sunagawa M., et al. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide- sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 333 (1997) 249-259
6. Follath F., Cleland J.G., Just H., et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study: a randomized double-blind trial). Lancet 360 (2002) 196-202
7. Follath F., Franco F., and Cardoso J.S. European experience on the practical use of levosimendan in patients with acute heart failure syndromes. Am J Cardiol 96 (2005) 80G-85G
8. Nanas J.N., Papazoglou P.P., Terrovitis J.V., Kanakakis J., Dalianis A., Tsolakis E., et al. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone. Am J Cardiol 94 (2004) 1329-1332
9. Kiviko M., Lehtonen L., and Colucci W.S. Sustained hemodynamic effects of intravenous levosimendan. Circulation 107 (2003) 81-86
10. Chryssanthopoulos S., Dritsas A., and Cokkinos D. Activity questionnaires; a useful tool in accessing heart failure patients. Int J Cardiol 105 (2005) 294-299
11. Parissis J., Adamopoulos S., Antoniades C., et al. Effects of levosimendan on circulating proinflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 93 (2004) 1309-1312
12. Spargias K., Anifantakis A., Papadakis M., et al. Preliminary clinical experience with the repetitive administration of levosimendan in patients with end-stage heart failure. Ital Heart J 4 Suppl 2 (2003) 45S-49S
13. Slawsky M.T., Colucci W.S., Gottlieb S.S., et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 102 (2000) 2222-2227
14. Nieminen M.S., Akkila J., Hasenfuss G., et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 36 (2000) 1903-1912
15. Janssen P.M.L., Datz N., Zeitz O., et al. Levosimendan improves diastolic and systolic function in failing human myocardium. Eur J Pharmacol 404 (2000) 191-199
16. Singh B.N., Lilleberg J., Sandell E.P., Ylonen V., Lehtonen L., and Toivonen L. Effects of levosimendan on cardiac arrhythmia: electrophysiologic and ambulatory electrocardiographic findings in phase II and phase III clinical studies in cardiac failure. Am J Cardiol 83 (1999) 16-20
17. Parissis J.T., Adamopoulos S., Farmakis D., et al. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart 92 (2006) 1768-1772